Triumeq

Clinical description of ABC HSRs: 1

• Almost all patients developing ABC HSRs will have fever and/or rash
• Other key symptoms include: gastrointestinal, respiratory, or constitutional symptoms such as lethargy and malaise
  

If suspected: 1

• TRIUMEQ must be stopped without delay, even in the absence of the HLA-B*5701 allele
• After stopping treatment with TRIUMEQ for a suspected HSR, TRIUMEQ or any other medicinal product containing ABC or DTG, must never be re-initiated
  

Guidelines recommended: 34

• EACS and DHHS guidelines recommend screening for HLA-B*5701 before starting ABC-containing antiretroviral therapy, if not previously tested
  

For further information, please see the Summary of Product Characteristics. 

ABC=abacavir.
DTG=dolutegravir.
EACS=European AIDS Clinical Society.
DHHS=Department of Health and Human Services.

References:

1. TRIUMEQ Summary of Product Characteristics.
2. Mallal S, Phillips E, Carosi G, et al; for the PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med. 2008;358:568-579.
3. European AIDS Clinical Society Guidelines, version 7.02; http://www.eacsociety.org/Portals/0/140601_EACS%20EN7.02.pdf. Updated June 2014.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf. Updated May 1, 2014.